<DOC>
	<DOCNO>NCT00502034</DOCNO>
	<brief_summary>The aim study compare efficacy ( term event-free survival overall survival ) adjuvant therapy IFN-alpha plus low-dose IL2 v wait-and-see program patient radically operate renal cell carcinoma .</brief_summary>
	<brief_title>Low-dose IL-2 Plus IFN-alpha Immunotherapy Adjuvant Treatment Renal Carcinoma .</brief_title>
	<detailed_description>For pt non-metastatic RCC , standard adjuvant treatment exist . Immunotherapy ( IT ) use IFN and/or IL2 effective metastatic disease set . Low chronically repeat dos IL2 plus IFN induce persistent stimulation immune system relevant toxicity . Surgically treated RCC pt randomize follow arm : A ) low-dose IT ; B ) control arm . IT consist 4-week cycle s.c. IL2 ( 5 days/wk , 1 million UI/sqm bid 1,2 1 million UI/sqm x 1 3,4,5 ) + IFN ( 1,8 million UI/sqm 3,5 week ) . Cycles repeat every 4 month first 2 year every 6 month remain 3 year . Each patient receive 12 cycle 5 year . Inclusion criterion follow : histological diagnosis RCC , age &lt; 75 yr , radical partial nephrectomy within past 3 month , pT1 ( diameter T &gt; 2,5 cm ) , T2 , T3 a-b-c ; pN0-pN3 , M0 ; good cardiac renal function autoimmune disease .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Diagnosis histologically confirm renal cell carcinoma ( every histotype ) ; Age &lt; 75 year Radical surgical removal tumor : total partial nephrectomy within previous 3 month Patient classify T1 ( diameter &gt; 2,5 cm ) , T2 , T3 abc ; In presence involvement locoregional lymphnodes ( stag N1 , N2 , N3 , TNM class . ) , metastases completely remove nephrectomy Absence distant metastasis ; Written inform consent Tumor diameter equal le 2,5 cm ; Previous chemotherapy ormonotherapy immunotherapy ; Renal insufficiency &gt; 3 mg/dl ) ; No symptomatic arrhythmias autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Carcinoma , Renal Cell</keyword>
	<keyword>Low-dose Interleukin</keyword>
	<keyword>Adjuvant Immunotherapy</keyword>
</DOC>